BioCentury | Dec 2, 2020
Distillery Therapeutics

Neuraly’s GLP-1R agonist NLY01 for ocular hypertension

...team to study the GLP-1R agonist in other animal models of glaucoma.Neuraly, a subsidiary of D&D Pharmatech Co. Ltd....
BioCentury | Aug 14, 2019
Financial News

D&D raises $137M to fund inflammation tech out of JHU

...round to push forward the pipelines of its trio of inflammation-focused subsidiaries. Founded in 2014, D&D Pharmatech Co. Ltd....
...TNFRSF10B (DR5; TRAILR2; CD262) - Tumor necrosis factor receptor superfamily member 10b Elizabeth S. Eaton, Staff Writer D&D Pharmatech Co. Ltd. Neuraly...
Items per page:
1 - 2 of 2
BioCentury | Dec 2, 2020
Distillery Therapeutics

Neuraly’s GLP-1R agonist NLY01 for ocular hypertension

...team to study the GLP-1R agonist in other animal models of glaucoma.Neuraly, a subsidiary of D&D Pharmatech Co. Ltd....
BioCentury | Aug 14, 2019
Financial News

D&D raises $137M to fund inflammation tech out of JHU

...round to push forward the pipelines of its trio of inflammation-focused subsidiaries. Founded in 2014, D&D Pharmatech Co. Ltd....
...TNFRSF10B (DR5; TRAILR2; CD262) - Tumor necrosis factor receptor superfamily member 10b Elizabeth S. Eaton, Staff Writer D&D Pharmatech Co. Ltd. Neuraly...
Items per page:
1 - 2 of 2